PH-ILD patient registry: tracking real-world outcomes
Part of Heart & circulation, Lungs & breathing clinical trials.
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of lung scarring (fibrotic interstitial lung disease) confirmed by a CT scan, such as idiopathic pulmonary fibrosis or autoimmune-related ILD.
- You have been diagnosed with pulmonary hypertension (high blood pressure in the lungs) caused by your lung disease, confirmed by a right heart catheterization.
- You are willing to complete surveys and provide consent in English or Spanish.
- You may be able to join even if you are already taking part in another study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
This trial is a long-term follow-up study for people who already completed a previous study of an inhaled treprostinil medication (TPIP) for pulmonary hypertension caused by interstitial lung disease (PH-ILD). It tests whether continued treatment with TPIP is safe and effective over a longer period.
This trial tests an inhaled medicine (TPIP) for people with both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug helps improve exercise ability and symptoms.
This study is tracking people with pulmonary hypertension (high blood pressure in the lungs) over time to see how their condition and quality of life change. By joining, you help doctors better understand the disease and improve care for others like you.
This study is a registry that collects information on people with pulmonary hypertension who are using or starting targeted medications. The goal is to understand how these treatments work in real-world settings and improve care for patients like you.
This trial is a registry that collects health information from people with pulmonary hypertension to better understand the disease and improve care. You may be asked to share details about your diagnosis and visits, especially soon after you start seeing a specialized PH care center.
Hear when a new Pulmonary Hypertension Due to Lung Diseases and Hypoxia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.